May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
An Interpretation of Quality of Life Based on Binocular Visual Acuity in German Patients with Age–related Macular Degeneration
Author Affiliations & Notes
  • A.M. Pleil
    Worldwide Outcomes Research, Pfizer La Jolla Lab, San Diego, CA
  • J.C. Cappelleri
    Global Research & Development, Pfizer Inc, Groton, CT
  • J.A. Chisholm
    Global Research & Development, Pfizer Inc, New London, CT
  • C.A. Getter
    Global Research & Development, Pfizer Inc, Groton, CT
  • S. Lustig
    Global Research & Development, Pfizer Inc, Groton, CT
  • M.B. Reichel
    Augenabteilung Klinikum Konstanz, Konstanz, Germany
  • Footnotes
    Commercial Relationships  A.M. Pleil, Pfizer Inc E; J.C. Cappelleri, Pfizer Inc E; J.A. Chisholm, Pfizer Inc E; C.A. Getter, Pfizer Inc E; S. Lustig, Pfizer Inc E; M.B. Reichel, Pfizer Inc C.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1369. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.M. Pleil, J.C. Cappelleri, J.A. Chisholm, C.A. Getter, S. Lustig, M.B. Reichel; An Interpretation of Quality of Life Based on Binocular Visual Acuity in German Patients with Age–related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1369.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: We evaluated different functional forms of Snellen visual acuity (VA) in wet–form age–related macular degeneration (AMD) patients to explain variance in quality of life (QoL) scores measured by the 25–item National Eye Institute Visual Function Questionnaire. Method: 187 patients attending an ophthalmology clinic in Germany were included. Patients were allocated to 1 of 3 severity classes: 1) early AMD in both eyes (n=35); 2) late stage AMD in 1 eye and early stage AMD in the other eye (n=111); and 3) late stage AMD in both eyes (n=41). The coefficient of determination (r2) selection method (controlling for age, gender, number of comorbidities) from a multivariate linear regression was used to select the measure of VA that explained the greatest variance in QoL domain and composite scores. The variants of VA evaluated were 1) the best overall weighted VA measure; 2) unweighted algebraic combinations of VA; and 3) the appropriate functional form between the chosen VA metric and NEI VFQ scores. Results: In explaining variation in QoL scores, the weighted VA measure of 0.75 in the better eye and 0.25 in the worse eye was generally most informative. Of all weighted VA measures, this variable (along with the covariates age, gender, number of comorbidities) explained the highest proportion of variance in General Vision (overall r2=0.42; incremental r2 [ir2] beyond covariates=0.37), Near Vision (r2=0.54; ir2=0.38), Distance Vision (r2=0.51; ir2=0.40), and Composite Score (r2 =0.51; ir2=0.36). For the other domains, the measure had r2 values that were virtually identical to other weighted measures of VA. In general, a quadratic relationship characterized the relationship between 0.75 and 0.25 weighted VA (best eye/worst eye) and QoL scores. Conclusion: The data suggest that a weighted model provides a better explanation of differences in vision–related QoL and likely is a better predictor of patient outcome than best eye only. These results show that there may be a measurable QoL benefit from early intervention in AMD.

Keywords: age–related macular degeneration • clinical (human) or epidemiologic studies: outcomes/complications • quality of life 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×